Trump’s proposed 100‑200% tariffs on generic drugs could raise U.S. drug prices and disrupt generic supply chains starting August 2028
Executive summary: On July 21, 2026, former President Donald Trump announced via Politico that he plans to impose tariffs on imported generic drugs, starting at 100% in August 2028 and rising to 200% a year later. Such tariffs could increase the cost of generic medicines for U.S. consumers, disrupt supply chains for generic drug manufacturers and importers, and provoke retaliatory measures from trading partners.
Who is involved: Former President Donald Trump, U.S. generic drug manufacturers, pharmaceutical distributors, and foreign generic drug producers.
Likely next: The proposal would need to be formalized through U.S. trade policy processes, with the tariffs slated to take effect in August 2028 and increase to 200% in August 2029 unless altered or challenged.
Former President Donald Trump told Politico that he intends to impose tariffs on imported generic drugs, beginning at a 100% rate in August 2028 and increasing to 200% a year later. The move, if enacted, would likely raise prescription drug costs in the United States and could trigger trade disputes with exporting nations. No formal proposal or legislative text has been released yet, leaving the timing and legal basis uncertain.
Timeline
- — Trump says he will impose tariffs on generic drugs starting in August 2028 (Politico Europe)
Analysis — what this means
Likely next events
- Tariff implementation scheduled for August 2028 at a 100% rate
- Increase to 200% planned for August 2029
Sectors affected
- Generic pharmaceutical manufacturers
- U.S. pharmaceutical distributors
- Importers of generic drugs
Regulatory implications
- The proposed tariffs would be enacted under existing U.S. trade authority
- Implementation would be subject to review by U.S. trade agencies and could face WTO dispute settlement
Historical parallels
- U.S. steel and aluminum tariffs under Section 232 (2018)
- U.S. Section 301 tariffs on Chinese goods (2018‑2019)
Sources
Related cases
- German Chancellor Friedrich Merz appoints Nina Warken as Chancellery Minister and Carsten Linnemann as Health Minister, but overlooks a key issue according to commentators
- A Ørsted‑sponsored Politico podcast featuring Ulf Poschardt spotlights the company’s role in shaping energy‑transition discourse
- Labour's prospects hinge on Andy Burnham amid rising Farage threat